Impax Appoints Christopher Mengler, R. PH., President of Global Pharmaceuticals Division

January 5, 2009

HAYWARD, Calif. January 5, 2009 – IMPAX Laboratories, Inc. announced today the appointment of Christopher Mengler, R.Ph., as President of Global Pharmaceuticals, the Company’s generic pharmaceutical division.  In this role, Mr. Mengler will be responsible for expanding the Company’s generic business by growing capability in the U.S. market while driving global opportunities.

Larry Hsu, Ph.D., president and chief executive officer of IMPAX said, “We are pleased that Mr. Mengler will be joining IMPAX and leading our generics division.  He is an accomplished executive with significant experience in key management positions including strategic planning and the development of Barr Laboratories generic R&D and commercial products portfolio.  His addition further enhances our management team and will help improve our business results.”

Mr. Mengler comes to IMPAX from Barr Laboratories, Inc., where he was most recently Executive Vice President, Global Strategic Planning, responsible for the global cross-functional development of the generic product portfolio.  He brings over 20 years of pharmaceutical experience to IMPAX, including key management positions with Pfizer and Sterling Winthrop.  He earned a B.S. in Mathematical Sciences and Operations research from Johns Hopkins University, a B.S. in Pharmacy from St. John’s University, and his MBA from Bernard M. Baruch College in New York.  

About IMPAX Laboratories, Inc.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and markets its branded products through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

 

Company Contacts:

IMPAX Laboratories, Inc.

Larry Hsu, Ph.D. President & CEO
(510) 476-2000, Ext. 1111
Arthur Koch, CFO ;
(215) 933-0351
Mark Donohue, Sr. Director IR
(215) 933-3526
www.impaxlabs.com